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Abstract 
Adoptive T cell therapy (ACT) is a safe and effective personalized cancer 
immunotherapy that can comprise naturally occurring ex vivo expanded cells (e.g. 
tumor infiltrating lymphocytes (TIL)) or T-cells genetically-engineered to confer 
antigen-specificity (T-cell receptor (TCR) or chimeric antigen receptor (CAR) 
engineered T-cells) to mediate cancer rejection. 
In recent years some ACT have produced unprecedented breakthrough responses: 
TIL therapy has moved from melanoma to solid tumor applications, TCR-engineered 
cells are developed for hematologic and solid tumors, and CAR-engineered T cells 
have received FDA-approval for the treatment of patients with certain B cell 
malignancies. Although results are encouraging, to date, only a small percentage of 
patients with advanced malignancies can benefit from ACT. Besides ACT availability 
and accessibility, treatment-related toxicities represent a major hurdle in the wide 
implementation of this therapeutic modality. 
The large variety of observed toxicities is caused by the infused cell product or as side 
effects of accompanying medication and chemotherapy. Toxicities can occur 
immediately or delayed.  
In order to render those highly promising therapeutic approaches safe enough for a 
wider pool of patients outside of clinical trials, an international consensus for toxicity 
management needs to be established.  
 
Key Points: 
Our work provides an overview over important toxicities of adoptive cellular 
immunotherapy.  
We introduce the concepts of TIL, TCR and CAR ACT.  
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We discuss toxicity pathomechanisms and review up-to date treatment strategies. 
 
 
1. Introduction 
T-cells harbor  great potential to treat cancer [1]. So-called adoptive cell 
immunotherapy (ACT) uses T-cells isolated from patients’ tumors (tumor-infiltrating 
lymphocytes or TILs) or genetically engineered with T-cell receptors (TCRs) or 
chimeric antigen receptors (CARs) [2].  
TIL therapy employs naturally occurring T cells and has been established over decades 
with very promising results largely in melanoma [3, 4], but also ovarian cancer [5-7] 
and colorectal cancer [8, 9]. In contrast to TILs, gene transfer-based T-cell therapy 
strategies have been developed to confer new target specificity to peripheral blood T 
cells (Fig.1), and new generations of CARs provide increased functionality to overcome 
tumor-specific immune tolerance. TCRs recognize peptides derived from tumor-
associated antigens (TAAs) presented in the context of human leukocyte antigen 
(MHC)-restricted antigen peptides [10, 2, 11]. CARs are antibody recognition domains 
linked to TCR and other costimulatory signaling molecules (Fig.2b) [12-14]. Both have 
been shown effective in refractory tumors [10, 15].  
For all three ACT approaches discussed in this review, T cells are expanded ex vivo 
and re-infused in large numbers into a lymphodepleted cancer patient (Fig.1 [2]), 
although TCR-ACT has been effective without lymphodepletion as well [16]. 
Lymphodepleting chemotherapy before TIL infusion reduces regulatory T cells (Treg) 
and resident tumor microenvironment cells competing for T-cell homeostatic cytokines, 
increases the levels of Toll-like-receptor ligands [17, 18], and favors the proliferation of 
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the infused T-cells through homeostatic expansion. This translates into a markedly 
improved T-cell survival and response rate and duration in melanoma [19, 20]. 
After treatment with TIL and in most TCR-ACT clinical trials, patients receive high-dose 
interleukin 2 (IL-2) in order to bolster T-cell division expansion within the host (Fig.1). 
TIL and engineered T cells (TCR and CAR) are currently applied mainly within clinical 
trials at highly specialized centers. The landscape is nonetheless rapidly evolving. In 
August 2017, the FDA approved the first anti-CD19 CAR‑T‑cell product, 
tisagenlecleucel (Kymriah, Novartis, Basel, Switzerland), for the treatment of pediatric 
and young adult patients with relapsed and/or refractory B-cell precursor acute 
lymphoblastic leukemia [21]. In October 2017 a second anti-CD19 CAR, axicabtagene 
ciloleucel (Yescarta, Kite Pharma, Santa Monica, CA, USA), was approved by FDA for 
the treatment of adult patients with relapsed or refractory large B-cell lymphoma after 
two or more lines of systemic therapy. Both products received approval in Europe in 
2018. Despite great promise and rapid development of ACT, treatment related 
toxicities remain an important issue. Preventing or managing unwanted toxicity has 
therefore emerged as a key component in the successful clinical application of these 
technologies. This article will review the treatment principles and toxicities of the three 
most prominent classes of ACT: TILs, TCR-engineered T cells, and CAR T cells. 
 
2. Tumor infiltrating lymphocytes (TILs) 
2.1 Treatment principle  
TIL therapy consists of the administration of autologous ex-vivo expanded T cells that 
naturally infiltrate tumors. Fig.1 illustrates the general sequence of TIL ACT: Following 
surgical resection of a suitable lesion, TILs are isolated, cultured and expanded ex vivo 
in the presence of IL-2 to generate a T-cell product of predominantly T effector-memory 
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cells [22]. Before TIL reinfusion, patients undergo lymphodepleting chemotherapy. 
High doses of recombinant IL-2 are administered after TIL reinfusion to facilitate TIL 
expansion and engraftment in vivo. Response rates appear higher in patients treated 
with minimally-cultured “young” TIL that retain a higher proliferative potential and a 
higher lytic activity [23].  
Most lymphodepleting regimens consist of fludarabine and cyclophosphamide; as an 
example, the NIH Surgery Branch regimen combines 5 days of 25mg/m2 fludarabine 
(D-7 to D-3) and 2 days of 60mg/kg cyclophosphamide (D-7, D-6, Fig.1) [9]. After 
completion of TIL infusion, patients are treated with IL-2, usually administered as bolus 
infusions; the largest dataset originates from high-dose (HD) IL-2 (typically boluses of 
≥ 600,000 IU/kg), although low-dose regimens (≤ 600,000 IU/kg) have been described 
[24, 25, 19, 26, 27, 4]. Most patients treated receive between two and ten doses of 
high-dose IL-2, with a median of approximately six doses [28, 25-27, 29, 30, 4]. 
Usually, an interval of 8 hours is chosen between doses.  
 
2.2  Clinical results and applications 
While most TIL clinical trials from 1988 to date have been for metastatic melanoma 
[28, 25-27, 29, 30, 4], they have also been reported for renal cell carcinoma, breast 
cancer and colorectal cancer [8, 9]. Overall response rates in melanoma patients, 
mostly highly pretreated, ranged from 27.5% to 57%, and complete response rates 
from 6.4 to 22% [28, 24-26, 31, 29, 30]. Median overall survival was either not reached 
at the time of publication or rather variable and ranged from 8.5 month [31] to 16.4 
month [28] in treated and evaluable patients. Two-year overall survival was reported 
as 40% in two studies [25, 31]. It should be mentioned that most studies have not 
reported results as an intent-to-treat analysis, with 20-40 % [28, 24, 25, 19, 26] of 
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patients being taken off study due to rapid disease progression before TIL reinfusion, 
or unsuccessful TIL expansion [28]. Furthermore, few studies have comprehensively 
described toxicity, the majority reporting only on grade 3 or higher adverse events. 
 
2.3 Toxicities  
TIL therapy requires an inpatient hospital stay with a median duration of 20 days [28, 
26]; patients are discharged upon hematologic and other systems’ recovery. Non-
myeloablative lymphodepleting chemotherapy causes both hematological and non-
hematological toxicities. Transient cytopenia including neutropenia, lymphopenia as 
well as prolonged depression of CD4+ T cells are observed in virtually all patients [28, 
24-27, 31, 29, 30, 32, 4, 9]. Neutropenic fever occurs in 37 - 51% of patients [24, 26]. 
G-CSF as well as blood product support is routinely required, with a median of five red 
blood cell transfusions and 30 units of platelets [28, 24-27, 31, 29, 30, 32, 4, 9] (Table 
1). Side effects are managed according to standards of good clinical practice [33]. In 
the absence of prophylaxis, a minority of patients experience opportunistic infections, 
including Pneumocystis jirovecii pneumonia (e.g. 6% in [26]) or Herpes zoster 
reactivation (e.g. 9% in [26]), thus mandating routine prophylaxis for a minimum 
duration of 6 months post-chemotherapy. Non-hematological high-grade toxicities 
include diarrhea (e.g. 12 % in [28]), hyperbilirubinemia (e.g. 14% in [28]) and 
fludarabine-induced neurotoxicity [28, 25, 26]. The overall mortality from this regimen 
is less than 1% [25, 27]. 
High-grade toxicity attributed to the TIL infusion product itself is exceedingly 
uncommon. Immediate infusion reactions to TILs are rare and mainly low grade [34, 
35, 26, 27, 36, 37, 32, 2, 38, 9, 39], and they are difficult to discriminate from early 
reactions to low residual levels of IL-2 remaining in the TIL product after ex-vivo culture. 
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Allergic reactions include acute release of cytokines with fever, skin reaction and 
dyspnea or delayed symptom onset. Management is symptomatic and use of 
corticosteroids discouraged. In case of a side effect related to TIL-infusion, every effort 
should be taken not to stop the cell infusion, if the clinical symptoms allow it [40, 41, 2] 
(Table 1). Autoimmune melanocyte destruction, manifesting as vitiligo or uveitis may 
occur in approximately 35% and 15% of patients, respectively [26]. 
High-dose IL-2 is associated with transient and typical dose-limiting toxicity. Both 
efficacy and toxicity are dose- and schedule-dependent (reviewed in [42-45]). Although 
high-dose IL-2 is associated with significant morbidity, the incidence and severity of 
toxicities have decreased overall as more patients have been treated worldwide and 
clinicians have gained experience in the prevention and management of side effects 
[26, 32, 4, 45, 46] (Table 1). The implementation of lymphodepleting chemotherapy 
greatly limits the immediate IL-2 toxicity relative to an immunocompetent host, as it 
eliminates resident lymphocytes as a source of cytokines contributing to IL-2 side 
effects [19].  
Generally, toxicities associated with high-dose IL-2 therapy are transient and can be 
managed using standard interventions [43]. Infusion of IL-2 requires an adequate 
hospitalization setting offering hemodynamic and respiratory monitoring as well as 
personnel to conduct frequent physical examination, blood tests, and radiological 
imaging when required, according to protocol. IL-2 toxicity can manifest in multiple 
organ systems, most significantly the heart, lungs, kidneys, and central nervous 
system. The most common manifestation is capillary leak syndrome, resulting in a 
hypovolemic state and extravascular fluid accumulation. Most patients become 
tachycardic and hypotensive 4-6 hours after IL-2 administration, mimicking a sepsis-
like pathophysiology. Usual management includes cautious crystalloid fluid boluses 
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(max 1000-1500 ml/day), careful avoidance of fluid overload which can precipitate 
pulmonary edema due to capillary leak. Systolic arterial blood pressure can usually be 
stabilized to a new baseline of approximately 80-90 mmHg. Heart rate must generally 
return below 100 b/min before administering the next IL-2 dose [43]. Cardiac 
arrhythmias happen rarely. In case of transient atrial flutter or fibrillation, IL-2 
continuation is possible if rhythm returns to normal sinus rate. In case of ventricular 
arrhythmia, definitive discontinuation of IL-2 is mandatory. Capillary leak syndrome can 
contribute significantly to the development of oliguria, cardiac ischemia, dyspnea from 
pulmonary congestion (3-47%, [28, 25]) requiring intubation in 6 – 9% of patients [24, 
26] and mental status changes (confusion). Treatment is mainly supportive. In addition, 
thyroid dysfunction is a relatively common sequel of IL-2 therapy, with 9% of patients 
presenting hypothyroidism requiring hormone replacement, and 7% of patients 
presenting hyperthyroidism [47]. In rare severe cases, vasopressors, intubation or 
continuous hemofiltration may be indicated. Safe administration of high-dose IL-2 
depends on the experience of the caring team, adherence to standards of IL-2 
administration and patient assessment guidelines, and that patient-eligibility criteria are 
respected. Further, it is important to carefully asses vital parameters prior to each high-
dose IL-2 administration and strictly recognize and avoid contraindications as 
determined by the clinical study protocol [43, 45, 42, 46] (Table1). Toxicities 
accompanying TIL therapy are mostly low-grade, transient and manageable by 
standard supportive care but patients should only be treated in specialized centers. 
 
3. TCR-transduced T Cells  
3.1 Treatment principle  
9 
 
Antigen specificity of T cells is endowed by their TCR, which binds a cognate ligand 
consisting of a peptide presented in the major histocompatibility complex (MHC), the 
so-called pMHC complex. TCR-ACT consists of autologous T lymphocytes engineered 
ex-vivo to express an exogenous cancer-specific TCR (as described in Fig.1 and 
Fig.2a); this redirects autologous peripheral T cells to recognize a specific cancer 
antigen processed and presented on the context of the patient’s MHC. The use of 
peripheral T cells obviates the need to harvest and expand natural lymphocyte clones. 
A crucial determinant of both efficacy and safety is the affinity of the chosen TCR for 
its target pMHC. TCR in the upper end of natural affinity are associated with higher 
efficacy but affinity thresholds have been reported, beyond which T-cell activity levels 
drop, and cross-reactivity becomes an important risk [48]. The ideal pMHC target of a 
candidate TCR compromises a peptide from a tumor antigen that is exclusively 
expressed by cancer cells (expression in non-essential normal tissues may be 
tolerable), that is essential for cancer cell survival to reduce the risk of tumor escape 
through downregulation, and that is presented on frequent MHC molecules (reviewed 
in [49]). TCRs selected for gene modification are usually obtained from naturally 
occurring tumor-reactive T cell clones, although TCRs have also been isolated from 
mice transgenic for human HLAs that have been vaccinated with the targeted human 
antigen. In addition, the affinity of natural TCRs can be optimized by structure-based 
rational design [50] as well as by phage display screening technology [51, 52] (Fig.2a). 
Although successful in enhancing the performance of the transduced T cells against 
cancer, non-natural TCRs may also carry a higher risk of “off-tumor, on-target” toxicity 
(recognition of the pMHC expressed at low levels in normal tissues), or “off-tumor, off-
target” toxicity (cross-reactivity with a different pMHC expressed in normal tissues). 
Notably the mispairing of introduced TCR subunits with endogenous TCR subunits can 
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generate autoreactive T-cells [53, 54], but this can be minimized by optimal transgene 
design or gene-editing [55].  
For TCR-T cell ACT, peripheral T lymphocytes are activated and gene-modified to 
express the TCR, and then expanded in culture. As described in the TIL section, 
patients are usually pretreated with lymphodepleting chemotherapy, and high-dose IL-
2 may be administered after cell transfer. In sharp contrast to autologous TIL therapy, 
the genetic engineering of the T cells to express specific TCRs may lead to a high rate 
of toxicity mediated by the cell product itself due to autoreactivity, as discussed above. 
Rigorous pre-clinical testing is performed in order to negatively select autoreactive 
TCRs [49].  
 
3.2 Clinical results and applications 
Several TCR-ACT clinical trials have been conducted (Table 2) in patients with 
melanoma [56-58, 10], colorectal cancer [59], esophageal cancer [16, 60, 61], other 
carcinomas [62, 60], advanced multiple myeloma [63], acute myeloid leukemia and 
myelodysplastic syndrome [64]. While the targeting of tissue differentiation antigens 
such as MART-1 has had limited success, TCR against cancer-germline antigens such 
as melanoma-associated antigen (MAGE)-A3 [58, 60, 61], and New York esophageal 
squamous cell carcinoma (NY-ESO)-1 [63, 65] have demonstrated high response rates 
between 23% and 80% with rare durable and complete responses.  
 
3.3 Toxicities  
Toxicities resulting from lymphodepleting chemotherapy and high-dose IL-2 were 
described in the TIL section. The infused T cells can cause acute cytokine release 
syndrome (CRS), as well tissue directed autoimmune reactions [66]. Cytokine release 
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is triggered by the engagement of infused T cells with the targeted tumor cells (Table 
1 and CAR section), and its severity depends on the number and fitness of infused T 
cells, their avidity for the tumor antigen and the tumor bulk. The resulting clinical picture 
is a systemic inflammatory response syndrome, characterized by fever, tachycardia, 
hypotension, vasodilation and capillary leak [66]. Severe forms of CRS can progress 
to shock and fatal multi-organ failure. Management is similar to that for responding to 
side effects of high-dose IL-2, described above (Table1) and which has been reviewed 
extensively in the literature [43, 42, 46]. Mild forms of CRS can be treated with non-
steroidal anti-inflammatory drugs and anti-pyretic drugs. 
The nature of autoimmune toxicity is largely dependent on the target antigen of the 
TCR. For example, severe adverse events have been reported when TCR-ACT was 
directed against lineage antigens, i.e. antigens overexpressed in tumors but also 
expressed at low levels by the normal tissue of origin. For example, high-grade on-
target colitis was reported upon administration of TCR-transduced T cells targeting 
carcinoembryonic antigen (CEA), expressed highly in gastrointestinal cancers but also 
at low levels in the normal intestine [59], while on-target skin reactions were observed 
with TCRs against melanoma specific antigens MART-1 and gp100 [56, 57], also 
expressed by normal melanocytes.  
Careful selection of the target and the TCR mitigates the risk of excess toxicity during 
clinical development (Fig.2a). Commonly targeted and potentially safe antigens for 
TCR ACT include oncoviral antigens, cancer germline (testis) antigens such as NY-
ESO-1 and tumor neo-antigens [67]. Oncoviral antigens are highly immunogenic, but 
only present in 10-15% of all malignancies; TIL specific to EBV epitopes resulted in 
high response rates with durable responses in patients with EBV-associated 
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nasopharyngeal carcinoma [36], while anti-HPV specific TIL administered in metastatic 
cervical cancer evoked durable complete responses [38].  
Cancer germline antigens are normally expressed in gonads and the thymus but some 
exhibit cancer-specific expression and are shared among many tumor types [68, 65]. 
MAGE-A3 and NY-ESO1 have been targeted in metastatic melanoma, metastatic 
synovial sarcoma, or multiple myeloma [61, 65]. Since the affinity of the wild-type TCRs 
to these targets is usually weak, affinity-enhanced TCRs have been generated to 
increase anti-tumor activity, bearing the risk of losing strict specificity and generating 
cross-reactivity with other self-antigens. Thus far, anti-NY-ESO1 TCR T-cells have 
demonstrated a clinical benefit without toxicity [63, 65]. However, treatment of 
melanoma patients with a HLA-A*0201 restricted TCR directed against the germline 
antigen MAGE-A3 produced lethal neurotoxicity; deep characterization of the 
molecular basis for the toxicity revealed that the TCR recognized also HLA-A*0201 
epitopes in MAGE-A9 and A12, and that MAGE-A12 was expressed in human brain 
(in addition to possibly MAGE-A9) [61]. Furthermore, lethal off-target cardiotoxicity was 
observed in patients receiving ACT with an HLA-A*01 restricted TCR against MAGE-
A3 due to unexpected cross-reactivity of the TCR with a titin epitope in the HLA-A*01 
background, exclusively expressed in the heart in beating cardiomyocytes [69, 58].  
In order to limit on-target toxicity for oncoviral and germ-line antigens, their absence 
from panels of healthy tissue is tested in silico, using online databases (Human Protein 
Atlas, CGA database) and in vitro using PCR cDNA libraries and IHC in tissue panels 
[70, 49]). TCRs are tested against random epitopes and allogeneic MHC molecules 
using for example lymphoblastoid B cell lines with various MHC allotypes [71, 72]. 
Further testing for self-avidity and efficient cellular processing and presentation is 
recommended [49] as well as screening against a combinatorial peptide library and 
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additional cell subsets to detect off-target toxicity due to cross-reactivity [73]. Various 
techniques to reduce the risk of mispairing [74], including siRNA induced silencing of 
endogenous TCR [75] have been described.  
Neo-antigens resulting from somatic DNA alterations in cancer cells are by definition 
tumor-specific and are potentially recognized by a high-affinity T-cell repertoire, and as 
such represent attractive targets for immunotherapy both for their safety and efficacy 
[76, 77]. Neo-antigens are mostly patient-specific, i.e. with very few being shared 
among patients; their utilization, however, requires high-throughput methods for neo-
epitope and TCR identification. [78, 76, 79]. The rapid development of whole genome 
sequencing approaches might help to find neo-antigen targets for ACT from circulating 
tumor DNA (reviewed in [80]). Very recent developments in molecular-genetic 
methodology like CRISPR/CAS9 genetic engineering could prove useful for supporting 
the development of personalized TCR-ACT and there is currently a first trial recruiting 
at NIH using individual TCRs (ClinicalTrials.gov Identifier: NCT03412877).  
Management of toxicities depends on the organ system involved as well as the type of 
toxicity. In reported clinical trials, side effects resulting from on-target toxicity as 
reported after the MAGE-3 TCR study were managed using symptomatic therapy (for 
example for seizure control) and immunosuppression using corticosteroids [61]. Efforts 
to limit toxicity by inducible T-cell suicide are discussed in chapter 5 below. 
 
4. CAR T cells 
4.1 Treatment principle  
A CAR combines an extracellular antigen-binding domain, which typically comprises a 
single-chain variable fragment (scFv) from a monocolonal antibody, or a natural ligand 
[81] that confers recognition of a tumor-associated antigen, with an intracellular domain 
carrying signaling motifs capable of T cell activation and costimulation [12]. Currently, 
14 
 
the most common method of ex-vivo genetic engineering of T cells is via lentiviral and 
gamma-retroviral vector based transduction methods [82-85]. These allow for stable 
integration of the desired transgene(s). Alternative non-viral delivery technologies 
include electroporation for transient expression [86], and transposon/transposase 
delivery systems which allow larger gene-cargo [87, 88]. 
In contrast to TCRs, CARs can recognize any molecule present on the surface of target 
tumor cells in a non-MHC restricted manner. MHC-independent antigen recognition 
enables CAR-modified T cells to treat any patient whose tumor expresses the target 
antigen, and thus, unlike TCR-ACT, CAR-ACT permits the treatment of tumors that 
have acquired defects in antigen processing and MHC presentation [89]. While antigen 
recognition by CARs occurs by engagement of larger epitopes, imparting less risk of 
cross-reactivity [90], solid tumors remain an important challenge for CAR therapy as 
there exist few bone fide tumor antigens, thus running the risk of on-target/off-tumor 
toxicities (Fig.2b). 
 
4.2 Clinical results and applications: 
Administration of CAR-modified T cells that target the B-cell lineage differentiation 
antigen CD19 (CAR19) has led to impressive clinical responses in patients with acute 
B-cell leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma and 
other non-Hodgkin lymphomas [91-96, 15, 97], which led to their regulatory approval. 
CAR19 has therefore entered the mainstream and is a valuable therapeutic option for 
patients with hematologic malignancies.  
  
4.3 Toxicities  
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Toxicities arising from CAR therapy include toxicity from lymphodepleting 
chemotherapy, as described in the TIL section, cytokine release syndrome (CRS) and 
CAR T cell related encephalopathy syndrome (CRES) and auto-immune events. CRS 
is the most commonly observed toxicity. While in the majority of cases CRS presents 
mild, as a flu-like disorder with fever, malaise, headache, tachycardia and myalgias, in 
a proportion of patients it can rapidly evolve into a sepsis-like symptomatology, with 
vascular leak, hypotension, rash, pulmonary edema, systemic coagulopathy and multi-
organ failure [98]. The severity of CRS correlates with tumor burden [21]. Most 
toxicities are grade 1-2 and manageable [99]. Some predictive biomarkers for the 
occurrence of CRS like the dose of infused CAR-T cells, disease burden or preexisting 
endothelial activation have been established but warrant further clinical trials for their 
validation [100]. 
Since algorithms for accurate and consistent grading and management of the toxicities 
were lacking, a CARTOX (CAR-T cell therapy associated toxicity) working group has 
been formed and guidelines for diagnostic, grading and treatment of toxicities have 
been published in 2018 [99]. This review also includes a list of lethal events observed 
to date in CAR T-cell trials. The same working group presented CAR treatment 
guidelines for pediatric patients [101]. The magnitude and timing of the toxicities 
associated with CAR T cell therapy vary considerably across different CAR T cell 
constructs and across different diseases (acute lymphocytic leukemia (ALL) versus 
NHL) [102]. For example in the pivotal multicentre ZUMA‑1 trial of a CAR19 bearing 
the CD28/CD3ζ (28/ζ) endodomain in 101 patients with refractory aggressive B‑cell 
NHL, the rates of grade ≥3 CRS and neurological toxicities were 13% and 28%, 
respectively [103]. Conversely, in an interim analysis of the JULIET trial of a CAR19 
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bearing the 4‑1BB/CD3ζ (BB/ζ) endodomain in 51 patients with relapsed or refractory 
DLBCL, these rates were 26% and 13% [104]. 
Symptoms of CRS can be graded according to Lee [105]. Rarely CRS can develop 
into a fulminant haemophagocytic lymphohistiocytosis (HLH), characterized by 
hepatosplenomegaly, hepatotoxicity, jaundice and diffuse lymphoadenopathy, or 
macrophage activation syndrome (MAS), with high fever, hepatosplenomegaly, 
hepatotoxicity, jaundice, coagulopathy, hypofibrinogenemia, cytopenia, 
hypertriglyceridemia and extreme hyperferritinemia. Plasma levels of interleukin-6 (IL-
6), IL-10 and interferon-gamma (IFN) have been found to be very high during CRS 
[106], and they also correlate closely with the expansion and persistence of CAR T 
cells [107] . Although IFN likely is produced directly by CAR T cells, IL-6 is contributed 
largely by activated macrophages, which must persist despite chemotherapy according 
to recent preclinical studies [108, 109]. Given the potential key role of macrophages in 
CRS induced by CAR T cells, it has been recommended that candidate patients be 
screened for hereditary mutations predisposing to HLH, including PRF1, MUNC13-4, 
STXBP2, and STX11 [98]. 
Intensive monitoring and prompt management of toxicities are essential to minimize 
the morbidity and mortality associated with this potentially curative therapeutic 
approach (Table 2). Table 1 shows CRS treatment options according to Neelapu et al. 
[99]. Corticosteroids have been part of the management. The potential to attenuate the 
clinical efficacy of CAR T cells is a concern, although short-term steroid treatment did 
not appear to limit the efficacy of CAR T-cells [91, 106]. Blockade of IL-6 receptor (IL-
6R) with commercially available, FDA approved antibody tocilizumab, along with anti-
TNF antibody etanercept, produced prompt resolution of the symptomatology without 
affecting the expansion or efficacy of CAR T cells [106]. Effective IL-6 blockade can be 
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achieved also through siltuximab, a commercially available IL-6 blocking antibody [98]. 
IL-6 blockade is recommended to be administered early in case of CRS [110, 99]. 
Recent preclinical research shows that IL-1 is also required to trigger CRS [109, 108], 
indicating that IL-1 blockade might be useful in the management of CAR therapy 
toxicity.  
The second most worrisome CAR specific side effect is acute onset neurotoxicity 
termed CAR T cell-related encephalopathy syndrome (CRES), which can occur in 
association or independently of CRS. CRES is described as a biphasic phenomenon 
with a first phase that can occur together with CRS and is responsive to tocilizumab 
treatment, followed by a second phase that is not responsive to IL-6R blockade [99]. 
Early signs of CRES include decreased attention, coordination problems, agitation or 
delirium with preserved alertness, headache and language deficits. In the majority of 
cases symptoms resolve within four weeks, in more severe cases, cerebral edema, 
seizures, focal deficits and diminished consciousness including coma can occur. In 
133 patients receiving an anti‑CD19 CAR bearing the BBz endodomain, neurologic 
AEs (any) were recorded in 40%, presenting a median of four days after CAR-T cell 
infusion [111]. The highest grade neurotoxicity evolved within a median of one day 
from the onset of neurotoxicity, while the duration of reversible neurologic AEs was 
less than four weeks (median 5 days) in all but one patient. There were 4 deaths due 
to CRES: two from acute cerebral edema, one from disseminated intravascular 
coagulation and multifocal brainstem hemorrhage, and one from cortical laminar 
necrosis and coma. These largely occurred during the dose escalation phase of the 
study, in patients who received a dose of CAR T cells subsequently determined to be 
above the maximally tolerated dose. In over 90% of patients, neurologic AE presented 
in the presence of CRS, and patients without CRS only presented grade transient 1 
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neurotoxicity. In addition to CRS, the severity of neurotoxicity correlated with CAR T-
cell expansion in vivo, higher disease burden, higher dose of CAR T cells, and a 
fludarabine-containing chemotherapy preparative regimen. Severe CRS was a major 
risk factor for ≥grade 3 CRES, and plasma IL-6 levels greater than 500 pg/mL within 6 
days of CAR T-cell infusion were associated with ≥grade 4 neurotoxicity in 100% of 
patients [111].  
The pathophysiology mechanisms of CRES are under investigation. A careful review 
of clinical, laboratory and autopsy data from the above patients suggested that brain 
endothelial cell activation is an early event in CRES, which leads to breakdown of the 
blood-brain endothelial barrier and entry of inflammatory cytokines and CAR T cells in 
the brain, leading in severe cases to local severe inflammation, cerebral edema, 
hemorrhage and infarctions [111]. Mouse models have revealed that CRES is largely 
driven by activation of endogenous macrophages, recruited and activated by CAR T 
cells. Such monocytes produce IL-1 and nitric oxide, which drive the neurotoxicity, and 
monocyte depletion in the mouse prevented CRES. Tocilizumab could prevent 
systemic CRS but not the delayed-onset lethal CRES, while the IL-1 receptor 
antagonist anakinra could effectively reverse CRES in mice without affecting the anti-
leukemia efficacy of CAR T-cells [108, 109].  
The CARTOX working group developed algorithms for grading and management of 
CRES [99]. Treatment is symptom dependent. Anti-IL-6R therapy can be considered 
to relieve systemic toxicity of CRS. However, based on the recent mouse evidence, 
the use of IL-1 antagonist anakinra should be evaluated in the clinic. In higher grade 
CRES, administration of corticosteroids should be also considered [99].  
Severe immune-mediated adverse events, which can be on-target [80] or off-target (as 
explained in more detail the TCR section) following CAR T-cell infusion have been 
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appreciated. In order to limit on-target toxicity, careful selection of the target antigen is 
key, as discussed already in the TCR section of this article. Therapy with CAR T cells 
against carbonic anhydrase-9 (CAIX), for example, delivered to 12 patients with CAIX-
expressing metastatic renal cell carcinoma had to be stopped due to G2-G4 liver 
toxicity due to CAIX expression in the bile duct epithelium [112]. 
Several attempts have been made to limit toxicity from CAR-ACT through engineering 
solutions [113]. For example, the so-called split-signaling CARs entail the co-
transfection of T cells with two distinct CARs, one (zeta-CAR) that provides the main 
antigen binding ectodomain and a CD3 endodomain and a second (costimulatory-
CAR) that recognizes a second antigen on target tumor cells with a different 
ectodomain linked to a costimulatory endodomain. Engagement of the zeta-CAR 
drives suboptimal activation of T cells upon antigen recognition, while engagement of 
the costimulatory-CAR boosts T cell activation upon recognition of the second antigen. 
This combinatorial strategy therefore requires the simultaneous expression of the two 
antigens to fully activate CAR T cells, which occurs on the tumor, and avoids the CAR 
T cell activation against normal tissues which may express only one of the two antigens 
[114].  
 
5. Management of adoptively transferred T cells to reduce autoimmune 
toxicity   
Agents suppressing effector T cells could be useful in the management of acute TCR-
ACT autoimmune toxicities. Corticosteroids are most readily used, such as pulse 
corticosteroids (methylprednisolone) followed by a taper. Clinicians must also 
familiarize with drugs used in acute allotransplant rejection as further means to control 
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acute autommunity, including rabbit anti-thymocyte globulin (rATG-thymoglobulin), 
mycophenolate, tacrolimus and/or anti-CD52 antibody alemtuzumab [115].  
Additional safety strategy approaches include suicide genes which can eliminate CAR-
T or TCR T-cells on command [116]. For example, T cells transfected with the herpes 
simplex virus thymidine kinase (HSV-TK) can be subsequently eliminated by the use 
of the prodrug ganciclovir, which induces apoptosis specifically in HSV-tk transfected 
CAR-T cells. This has been successfully tested in clinical trials in order to avoid graft 
versus host disease after allogenic hematopoietic stem cell transplantation [117-119]. 
Another strategy employs an inducible caspase 9 suicide gene, integrated in the 
delivered transgene [120-122]. This particular suicide gene can be selectively activated 
by a chemical inducer of dimerization (CID) small molecule, which has been shown to 
increase safety in an allogenic stem cell transplantation setting [120] and is about to 
be tested in CAR-T cells in several phase I/II clinical trials (e.g. (NCT03639844)).  
Beside suicide gene engineering, T-cell death can be achieved using antibody-
dependent cell-mediated cytotoxicity (ADCC). A pre-clinically validated suicide 
strategy is retroviral delivery of the CD20 molecule into T cells, which allows targeting 
transduced T cells in vivo with anti-CD20 monoclonal antibody [123]. An alternative 
approach has combined epitopes from CD34 and CD20, enabling CD34 selection, cell 
tracking, as well as deletion after anti-CD20 monoclonal antibody administration [124]. 
Another approach has introduced a 10 amino acid tag of c-myc protein into the TCR 
sequence allowing elimination with anti-myc tag monoclonal antibody administration 
[125]. Finally, another approach has used truncated human EGFR polypeptide/anti-
EGFR monoclonal antibody [126]. The above methods rely on elimination of 
transduced T cells through ADCC, which can be slow especially following high dose 
21 
 
chemotherapy, and unable to control a rapidly expanding T cell population in the 
lymphodepleted host. 
 
6. Conclusions 
ACT immunotherapy shows great promise for treating and eradicating advanced 
metastatic cancers, but clinicians must familiarize themselves with its potential side 
effects. Except for CAR19, which is approved for B-cell malignancies in the US and 
Europe, all ACT is administered within clinical trials in specialized centers. Adverse 
events may be immediate or delayed, and although usually mild, they can be severe 
and persist for the duration of the genetically modified T-cell lifespan [127]. Unique to 
T cell therapies is the potential for extraordinary long-term persistence of transferred T 
cells for up to 10 years or longer [128, 129]. This persistence extends the promise for 
long-term surveillance of residual tumor cells and possible elimination and definitive 
cure of tumors, but also increases the timeline of potential toxicities far beyond those 
of chemotherapy or antibody based therapies. 
The rapidly growing knowledge regarding the interaction between the immune system 
and tumors, together with rapid advances in technology, will support the development 
of TIL, TCR- and CAR-T ACT to move toward the goal of treating cancer with high 
degree of safety, high efficacy and low cost. The CARTOX working group treatment 
algorithms for toxicity management in adults and pediatric patients provide guidelines 
for building the medical practice of CAR19 T cell therapy and offer a solid framework 
for establishing standardized and safe practices in the development of adoptive cell 
therapy with further CARs, TCRs and TILs.  
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Figure and Table legends 
Figure 1: Basic principles of adoptive cellular immunotherapy.  
Please note that high-dose IL-2 is administered in TIL ACT and administration is 
optional in TCR-T cell ACT. Lymphodepletive chemotherapy consisting of 
cyclophosphamide and fludarabine is administered in TIL and TCR-T ACT and optional 
in CAR-T ACT. PBL: peripheral blood lymphocyte. CAR: chimeric antigen receptor, 
TIL: tumor infiltrating lymphocytes, TCR: T-cell receptor, HD-IL-2: high dose interleukin 
2.  
 
Figure 2: TCR and CAR ACT. 
a: Schematic overview over the process of T-cell receptor engineering for TCR ACT. 
The upper row of boxes describes the steps in the engineering process; the boxes 
below describe safety measures that are applied in parallel in order to limit clinical 
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toxicity. TCR: T-cell receptor, ACT: adoptive cellular therapy. Adapted from Kapanen 
et al. 2015 [130].  
b: Schematic of components of endogenous TCR, genetically engineered TCR and 
CAR, TCR: T-cell receptor, CAR: chimeric antigen receptor. Adapted from June et al. 
2015 [13] 
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Table 1 
List of toxicities encountered in ACT by immune-depletive, non-myeloablative 
chemotherapy by fludarabine and cyclophosphamide, high doses of IL-2 and infused 
cell product as well as their management according to existing guidelines. ACT: 
adoptive cell therapy, CAR: chimeric antigen receptor, TCR: T-cell receptor, TIL: tumor 
infiltrating lymphocytes, IL-2: interleukin 2, G1-4: grading of symptom severity 
according to CTCAE (Common Terminology Criteria for Adverse Events).  
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Table 2 
Selected clinical trials using TCR ACT, encountered toxicities and their management.  
Column headings are: reference, trial ID, the treated disease (DISEASE), the major 
histocompatibility complex (MHC) used, the receptor origin, details of receptor 
generation, the T-cell origin, the number (n ) of patients, the observed treatment 
response, treatment related toxicities, the mechanism of toxicity, toxicity management, 
if IL-2 (interleukin 2) was administered (yes/no). 
MART-1: melanoma-associated antigen recognized by T cells, gp100: glycoprotein 
100, NY-ESO-1: New York esophageal squamous cell carcinoma 1, CEA: 
carcinoembryonic antigen, MAGE-A3: Melanoma-associated antigen 3, LAGE1: 
Cancer/testis antigen 2, WT1: Wilms tumor protein, TIL: tumor infiltrating lymphocytes, 
n.a.: not applicable, autol.: autologous, PBL: peripheral blood lymphocytes, AML: acute 
myeloid leukemia, MDS: myelodysplastic syndrome, CR: complete response 
according to RECIST, PR: partial response according to RECITS, SD: stable disease 
according to RECIST, HD: high dose 
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